UK – MSD’s pembrolizumab therapy gets NICE approval

1,500 people set to receive new skin cancer treatment that reduces the risk of it returning

An estimated 1,500 people aged 12 years and over with melanoma are set to benefit from MSD’s –  known as Merck & Co in the US and Canada – pembrolizumab (Keytruda), which reduces the chance of it returning, following guidance issued by the National Institute for Health and Care Excellence.

This is the first adjuvant treatment recommended by (NICE) for this stage of melanoma (2B and 2C) following surgery to remove the tumours. Stage 2 melanoma is defined as having deeply penetrating tumours that have not spread to the lymph nodes or to other parts of the body…